Comparative Pharmacology
Head-to-head clinical analysis: AEROLATE versus THEOVENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROLATE versus THEOVENT.
AEROLATE vs THEOVENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline competitively inhibits phosphodiesterase, increasing cAMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
Theovent is a brand name for theophylline, a xanthine derivative that acts as a bronchodilator by inhibiting phosphodiesterase, leading to increased intracellular cAMP levels, and by antagonizing adenosine receptors.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
Oral: 200-400 mg every 12 hours; maximum 800 mg/day. Intravenous: 200 mg loading dose over 30 minutes, then 200 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Terminal elimination half-life 7-9 hours, prolonged in patients with hepatic impairment (up to 12 hours) or heart failure.
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
Renal (70% as unchanged drug), biliary/fecal (30% as metabolites).
Category C
Category C
Bronchodilator
Bronchodilator